Precision oncology testing continues to expand as CareDx prepares to acquire Naveris for its NavDx HPV liquid biopsy MRD test, which is designed to detect HPV-driven cancer fragments in blood. The test received Medicare coverage in 2023 and is positioned for longitudinal molecular monitoring in specialty workflows. On the clinical imaging side, an FDA-focused policy shift and new trial workflows are paired with broader technology investment aimed at accelerating data handling and safety monitoring—an environment where molecular and diagnostic tools often benefit from tighter integration into trial and care pathways. The combination of liquid biopsy adoption and operational acceleration supports a broader shift toward monitoring-based oncology strategies rather than relying only on baseline diagnosis. For developers and labs, these moves reinforce that reimbursement coverage, workflow fit, and regulatory momentum are increasingly tied to commercial success.